Check out our free and informative ezines and sign up now
Savient Pharmaceuticals has filed its second citizen petition with the FDA in two years to block generic versions of its anti-weight-loss drug Oxandrin.
This article is viewable by subscribers only. To view this article, please select an option below.
ePublishing :: CMS, Hosting & Web Development | © Copyright